^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Oral Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + sitravatinib (MGCD516) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SNOW: Sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study
Published date:
05/13/2020
Excerpt:
Best responders (Pts S1-S2) had higher % of PD-L1+ TAMs at baseline.
DOI:
10.1200/JCO.2020.38.15_suppl.6569
Trial ID:
